Genome Editing Market: Focus on Technology - Distribution by Type of Gene Editing Technique, Type of Therapy, Gene Editing Approach, Type of Gene Delivery Method, Gene Delivery Modality, Application Area, Type of End User, Key Geographical Regions and Distribution by Type of Payment Method Employed: Industry Trends and Global Forecasts, 2023-2035
The genome editing market is expected to reach USD 3.5 billion by 2023 anticipated to grow at a CAGR of 12.6% during the forecast period 2023-2035.
Genome editing, also known as gene editing, is a genetic engineering technique that allows for the modification of a single gene or a sequence of genes within an organism's genome. In recent years, there has been a growing need for precise genome editing, leading to the development of various tools by gene-editing companies, such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR technology. These tools have been widely used to address clinical conditions resulting from genetic abnormalities, including sickle cell disease, Parkinson's disease, hearing loss, peripheral artery disease, spinal muscular atrophy, autoimmune diseases, and other genetic disorders. Gene therapy, with over 300 candidates in clinical trials as of 2023, has emerged as a promising option. In addition, Prophylaxis treatment is another segment that has garnered significant attention in the gene editing market. However, the development of gene-edited drug products requires substantial investment in drug discovery, development, and manufacturing. To ensure the efficient, precise, and safe delivery of these drugs, pharmaceutical companies are relying on novel genome editing technologies developed by genome editing companies. This is expected to improve the clinical outcome of therapeutics by achieving the desired genetic manipulation. With promising results in clinical trials and accelerated drug approvals, the genome editing market is projected to experience significant growth in the coming years.
Report Coverage
The report examines genome editing market by categorizing it based on type of gene editing technique, type of therapy, gene editing approach, gene delivery method, gene delivery modality, application area, type of end user, key geographical regions and payment method employed.
It evaluates the factors impacting market growth, such as drivers, restraints, opportunities, and challenges.
The report analyzes the potential benefits and barriers within the market and provides insights into the competitive landscape for leading market players.
It forecasts market segment revenues across three major regions.
Perform a comprehensive market analysis of genome editing companies, outlining essential parameters like founding year, company size in terms of workforce, headquarters location, operational model, type of gene editing technique (CRISPR-Cas system, meganucleases, TALENs, ZFNs and other techniques), gene editing approach, type of gene delivery method, type of gene delivery modality, highest phase of drug development supported, therapeutic area and application
Offer comprehensive profiles of genome editing companies, including an overview, establishment year, workforce count, headquarters location, key executives, technology portfolios, recent advancements, and future prospects.
Conduct a competitive analysis based on service tenure, competitiveness index encompassing type of gene editing technique, gene editing approach, in-silico (CADD) analysis, type of gene delivery method, type of gene delivery modality, highest phase of development supported and application area.
Analyze recent partnerships within the sustainable packaging market (2018-2023), considering partnership years, models (licensing agreements, research and development agreements, technology integration agreements, etc), partner types, active companies, agreement types, and regional distribution.
Examination of investments received by genome editing players from 2018 to 2023 details funding instances, amounts, funding types, investors, active players, active investors, and geographical distribution.
Detailed analysis of patents filed or granted in genome editing domain, considering parameters such as patent types, years, regions, applicant types, leading assignees, benchmarking, and valuation.
Key Market Companies
Arcturus Therapeutics
Avectas
Beam Therapeutics
Bio-Sourcing
Caribou Biosciences
Century Therapeutics
CRISPR Therapeutics
EdiGene
Editas Medicine
Flash Therapeutics
Fortgen
G+FLAS Life Sciences
Graphite Bio
Intellia Therapeutics
Ntrans Technologies
OXGENE
Prime Medicine
Revvity (formerly known as Horizon Discovery)
TargetGene Biotechnologies
Vor Biopharma
ZeClinics